Eskalith Cr

   
Google
 
Web NewDrugInformation.com

Eskalith Cr


Drug - Eskalith Cr
The trade name of the product as shown on the labeling.

Dosage - TABLET, EXTENDED RELEASE; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Lithium Carbonate
Multiple ingredients are in alphabetical order.

Strength - 450MG
The potency of the active ingredient(s), Lithium Carbonate. May repeat for multiple part products.

Applicant - GLAXOSMITHKLINE
The firm name holding legal responsibility for Eskalith Cr. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 018152
The FDA assigned number to Eskalith Cr. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Eskalith Cr. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code - AB
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Mar 29, 1982
The date Eskalith Cr was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Eskalith Cr. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Eskalith Cr is in. Format is RX, OTC, DISCN.

Applicant Full Name - Glaxosmithkline
The full name of the firm holding legal responsibility for the new application of Eskalith Cr.

Eskalith Cr